Ekso Bionics Holdings, Inc. (EKSO): Price and Financial Metrics

Ekso Bionics Holdings, Inc. (EKSO): $4.69

0.02 (+0.43%)

POWR Rating

Component Grades














  • Sentiment is the dimension where EKSO ranks best; there it ranks ahead of 95.88% of US stocks.
  • The strongest trend for EKSO is in Growth, which has been heading down over the past 48 weeks.
  • EKSO ranks lowest in Quality; there it ranks in the 7th percentile.

EKSO Stock Summary

  • Ekso Bionics Holdings Inc's market capitalization of $59,100,349 is ahead of merely 8.3% of US-listed equities.
  • The volatility of Ekso Bionics Holdings Inc's share price is greater than that of 87.84% US stocks with at least 200 days of trading history.
  • Ekso Bionics Holdings Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -69.81%, greater than the shareholder yield of only 3.89% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ekso Bionics Holdings Inc are LMND, XENT, STIM, NVRO, and XXII.
  • Visit EKSO's SEC page to see the company's official filings. To visit the company's web site, go to www.eksobionics.com.

EKSO Valuation Summary

  • EKSO's price/sales ratio is 6.5; this is 42.73% lower than that of the median Healthcare stock.
  • Over the past 90 months, EKSO's price/sales ratio has gone down 61.8.
  • EKSO's price/sales ratio has moved down 61.8 over the prior 90 months.

Below are key valuation metrics over time for EKSO.

Stock Date P/S P/B P/E EV/EBIT
EKSO 2021-08-31 6.5 1.5 -9.4 -2.7
EKSO 2021-08-30 6.3 1.5 -9.1 -2.4
EKSO 2021-08-27 6.4 1.5 -9.1 -2.5
EKSO 2021-08-26 6.3 1.5 -9.1 -2.4
EKSO 2021-08-25 6.3 1.4 -9.0 -2.3
EKSO 2021-08-24 6.2 1.4 -8.9 -2.2

EKSO Growth Metrics

  • The year over year net income to common stockholders growth rate now stands at -109.01%.
  • Its 2 year price growth rate is now at -85.1%.
  • The 4 year net income to common stockholders growth rate now stands at 69.84%.
EKSO's revenue has moved down $1,216,000 over the prior 33 months.

The table below shows EKSO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 9.272 -8.616 -6.467
2021-03-31 9.325 -9.033 -16.961
2020-12-31 8.882 -8.755 -15.825
2020-09-30 10.349 -8.51 -14.57
2020-06-30 10.771 -11.809 -16.816
2020-03-31 11.769 -12.317 -8.115

EKSO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EKSO has a Quality Grade of D, ranking ahead of 8.49% of graded US stocks.
  • EKSO's asset turnover comes in at 0.242 -- ranking 100th of 104 Machinery stocks.
  • MOG.A, CECE, and XONE are the stocks whose asset turnover ratios are most correlated with EKSO.

The table below shows EKSO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.242 0.615 -1.072
2021-03-31 0.303 0.608 -2.750
2020-12-31 0.426 0.571 -2.648
2020-09-30 0.489 0.538 -2.401
2020-06-30 0.529 0.511 -2.663
2020-03-31 0.556 0.493 -1.145

EKSO Price Target

For more insight on analysts targets of EKSO, see our EKSO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $11.00 Average Broker Recommendation 1.5 (Moderate Buy)

EKSO Stock Price Chart Interactive Chart >

Price chart for EKSO

EKSO Price/Volume Stats

Current price $4.69 52-week high $14.98
Prev. close $4.67 52-week low $3.96
Day low $4.60 Volume 113,000
Day high $4.94 Avg. volume 278,516
50-day MA $4.66 Dividend yield N/A
200-day MA $6.10 Market Cap 59.35M

Ekso Bionics Holdings, Inc. (EKSO) Company Bio

Founded in 2005 in Richmond, California, Ekso Bionics Holdings Inc employs approximately 92 people that design, develop, and sell wearable bionic human exoskeletons that have applications in healthcare, industrial, military, and consumer markets. The company’s first product, HULC was developed for the military in partnership with Lockheed Martin, enhancing soldier capabilities to allow them to carry heavier loads over further distances. The EksoNR is currently the only FDA-cleared exoskeleton for treatment of ABI, helping physical therapists, physiatrists, and doctors to clinically rehabilitate patients. The company’s CEO is Jack Peurach, who served as Executive Vice President, Products for SunPower Corp before becoming Ekso’s Chief Executive Officer.

EKSO Latest News Stream

Event/Time News Detail
Loading, please wait...

EKSO Latest Social Stream

Loading social stream, please wait...

View Full EKSO Social Stream

Latest EKSO News From Around the Web

Below are the latest news stories about Ekso Bionics Holdings Inc that investors may wish to consider to help them evaluate EKSO as an investment opportunity.

Ekso Bionics to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference

RICHMOND, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that management will participate in a fireside chat at the H.C. Wainwright 23 rd Annual Global Investor Conference held on September 13 - 15, 2021.

Intrado Digital Media | September 7, 2021

Medical Robotics Market size value in 2021, Revenue forecast in 2027 | By Prominent Players -Ekso Bionics Holdings Inc, Intuitive Surgical Inc, Stryker Corporation, Mazor Robotics Ltd, Accuray Incorporated

IBI did a detailed analysis of the medical robotics market and predicted its growth in the forecast period. Medical robotics permit specialists to all the more capably control carefully instruments or catheters inside the patient''s body during negligibly intrusive medical

OpenPR | September 1, 2021

Soft Robotics Market Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts to 2025- Soft Robotics Inc, - Righthand Robotics Inc, - Ekso Bionics Holdings Inc

16th August 2021, (Market Insight Report) - The Global Soft Robotics Market Research Report Forecast 2021-2025 is a valuable source of The Research, covers all the records worldwide and data for business strategists. It provides the Soft Robotics industry overview

OpenPR | August 16, 2021

Is Ekso Bionics Holdings (NASDAQ:EKSO) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...

Yahoo | August 9, 2021

Ekso Bionics (EKSO) Reports Q2 Loss, Tops Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -4.00% and 3.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 29, 2021

Read More 'EKSO' Stories Here

EKSO Price Returns

1-mo 1.30%
3-mo -20.24%
6-mo -20.37%
1-year 8.31%
3-year -86.10%
5-year -91.31%
YTD -23.49%
2020 4.52%
2019 -68.47%
2018 -41.78%
2017 -46.48%
2016 -44.26%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8528 seconds.